[go: up one dir, main page]

CR10555A - Vacunas para malaria - Google Patents

Vacunas para malaria

Info

Publication number
CR10555A
CR10555A CR10555A CR10555A CR10555A CR 10555 A CR10555 A CR 10555A CR 10555 A CR10555 A CR 10555A CR 10555 A CR10555 A CR 10555A CR 10555 A CR10555 A CR 10555A
Authority
CR
Costa Rica
Prior art keywords
protein
vivax
malaria
vaccines
monoclonal
Prior art date
Application number
CR10555A
Other languages
English (en)
Inventor
D Cohen Joseph
Marchand Martine
F Ockenhouse Christian
Yadava Anjali
Original Assignee
Glaxosmithkline Biolog Sa
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0614254.1A external-priority patent/GB0614254D0/en
Priority claimed from GB0614473A external-priority patent/GB0614473D0/en
Priority claimed from GB0614476A external-priority patent/GB0614476D0/en
Priority claimed from GB0615115A external-priority patent/GB0615115D0/en
Application filed by Glaxosmithkline Biolog Sa, Us Army filed Critical Glaxosmithkline Biolog Sa
Publication of CR10555A publication Critical patent/CR10555A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a una proteina novedosa hibrida/ de fusion derivada de la proteina CS de Plasmodium vivax (P. vivax), los procedimientos para preparar y purificar la misma, su uso en medicina, particularmente en la prevencion de infecciones de malaria, por ejemplo las provocadas por P. vivax, las composiciones/vacunas que contienen la proteina o anticuerpos contra la proteina tales como anticuerpos monoclonales o policionales y uso de los mismos, particularmente en terapia.
CR10555A 2006-07-18 2009-01-14 Vacunas para malaria CR10555A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0614254.1A GB0614254D0 (en) 2006-07-18 2006-07-18 Vaccine
GB0614473A GB0614473D0 (en) 2006-07-20 2006-07-20 Vaccines
GB0614476A GB0614476D0 (en) 2006-07-20 2006-07-20 Vaccine
GB0615115A GB0615115D0 (en) 2006-07-28 2006-07-28 Vaccines

Publications (1)

Publication Number Publication Date
CR10555A true CR10555A (es) 2009-04-29

Family

ID=38957130

Family Applications (2)

Application Number Title Priority Date Filing Date
CR10561A CR10561A (es) 2006-07-18 2009-01-14 Vacunas para malaria
CR10555A CR10555A (es) 2006-07-18 2009-01-14 Vacunas para malaria

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR10561A CR10561A (es) 2006-07-18 2009-01-14 Vacunas para malaria

Country Status (22)

Country Link
US (2) US9364525B2 (es)
EP (2) EP2040743B1 (es)
JP (2) JP5592110B2 (es)
KR (2) KR20090094213A (es)
AR (1) AR061894A1 (es)
AU (2) AU2007276219B2 (es)
BR (2) BRPI0715581A2 (es)
CA (2) CA2657353A1 (es)
CO (2) CO6150187A2 (es)
CR (2) CR10561A (es)
EA (2) EA200900033A1 (es)
ES (2) ES2437082T3 (es)
IL (2) IL196410A0 (es)
MA (2) MA30671B1 (es)
MX (2) MX2009000655A (es)
NO (2) NO20090177L (es)
NZ (2) NZ574239A (es)
PE (1) PE20080428A1 (es)
SG (2) SG173377A1 (es)
TW (1) TW200819462A (es)
WO (2) WO2008009650A2 (es)
ZA (1) ZA200900386B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
IL161584A0 (en) 2001-11-21 2004-09-27 Univ Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
WO2008009650A2 (en) * 2006-07-18 2008-01-24 Glaxosmithkline Biologicals S.A. Vaccines for malaria
KR20100108544A (ko) * 2007-12-06 2010-10-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
JP2011507817A (ja) * 2007-12-24 2011-03-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム マラリア用ワクチン
BRPI0919245A2 (pt) * 2008-09-24 2021-11-03 Us Gov Sec Army Vacina para malária
WO2010060719A1 (en) * 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
US8784832B2 (en) 2011-08-19 2014-07-22 University Of South Florida (A Florida Non-Profit Corporation) Synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein
GB201116248D0 (en) * 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
US9580482B2 (en) 2012-02-17 2017-02-28 Children's Medical Center Corporation Conformation-stabilized TRAP antigens
WO2014111733A1 (en) * 2013-01-21 2014-07-24 Isis Innovation Limited Composition and uses thereof
EP3213638A1 (en) 2016-03-01 2017-09-06 Coöperatie Avebe U.A. Vegan cheese analogue
GB201608821D0 (en) * 2016-05-19 2016-07-06 Isis Innovation Vaccines
ES2988600T3 (es) 2016-12-07 2024-11-21 Glaxosmithkline Biologicals Sa Proceso para elaborar una composición de liposoma que comprende una saponina
EP3559669A4 (en) * 2016-12-23 2020-11-18 The Walter and Eliza Hall Institute of Medical Research SYSTEM, METHOD, APPARATUS AND DIAGNOSTIC TEST FOR PLASMODIUM VIVAX
DE112020007612T5 (de) 2020-09-16 2023-06-29 Mitsubishi Electric Corporation Scheinwerfereinrichtung

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
DE3650242T2 (de) * 1985-07-12 1995-06-14 Univ New York Mit dem plasmodium-vivax-circumsporozoit-protein übereinstimmendes immunogenes peptidantigen.
US4826957A (en) * 1985-07-12 1989-05-02 New York University Immunogenic recombinant yeast expression product and method for purifying it
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
JPH0222300A (ja) * 1987-02-02 1990-01-25 Swiss Serum & Vaccine Inst Bern 免疫原性接合体およびその製法ならびに免疫を生ぜしめる方法
US4997647A (en) * 1987-03-30 1991-03-05 New York University Vaccine against the sporozoite stage of malaria
EP0362278A4 (en) 1987-06-05 1990-05-14 Us Health Autocrine motility factors in cancer diagnosis and management.
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US4977647A (en) * 1989-10-27 1990-12-18 D.B. Industries, Inc. Double locking snap hook
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
SG48390A1 (en) * 1991-11-16 1998-04-17 Smithkline Beecham Biolog Hybrid protein between cs from plasmodium and hbs ag
PL170980B1 (pl) 1992-06-25 1997-02-28 Smithkline Beecham Biolog Szczepionka PL PL PL PL PL PL PL
DE69405551T3 (de) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
CN1134173A (zh) 1993-09-10 1996-10-23 美国国有健康与人类服务部 间日疟原虫和镰状疟原虫红细胞结合蛋白的结合区
CN1055093C (zh) 1993-11-17 2000-08-02 实验室奥姆公司 葡糖胺二糖类、其制备方法和用途、以及含有这些二糖的药物组合物
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
GB9616351D0 (en) 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
US20030133944A1 (en) 2001-04-05 2003-07-17 Smithkline Beecham Biologicals S.A. Vaccine composition against malaria
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
EP1091928B1 (fr) 1998-06-30 2007-02-28 OM Pharma Nouveaux pseudodipeptides acyles, leur mode de preparation et les compositions pharmaceutiques en renfermant
KR20000020497A (ko) 1998-09-21 2000-04-15 임채승 말라리아의 검출방법
AU764969B2 (en) 1999-04-19 2003-09-04 Smithkline Beecham Biologicals (Sa) Vaccines
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
WO2001034188A1 (en) * 1999-11-12 2001-05-17 University Of Hawaii Malaria vaccine
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
GB0027088D0 (en) 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
EP1201250A1 (en) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
NZ530245A (en) 2001-06-22 2007-04-27 Wistar Inst Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
CA2502268A1 (en) 2002-10-23 2004-05-06 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
CA2507915C (en) 2002-12-17 2013-07-02 Crucell Holland B.V. Recombinant viral-based malaria vaccines
CA2528511C (en) 2003-06-20 2015-11-03 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
EP1638994B1 (de) 2003-06-20 2012-04-04 Siemens Healthcare Diagnostics Products GmbH NEUE OBERFLÄCHENPROTEIN- (HbsAg-) VARIANTE DES HEPATITIS B VIRUS
US20050233435A1 (en) * 2003-09-04 2005-10-20 Nyu Medical Center Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
US20060041248A1 (en) * 2004-08-23 2006-02-23 Patton David L Pharmaceutical compositions delivery system and methods
GB0420634D0 (en) 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
CA2593643C (en) * 2005-01-18 2016-03-22 Walter Reed Army Institute Of Research A plasmodium vivax hybrid circumsporozoite protein and vaccine
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
WO2008009650A2 (en) * 2006-07-18 2008-01-24 Glaxosmithkline Biologicals S.A. Vaccines for malaria
JP2011507817A (ja) * 2007-12-24 2011-03-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム マラリア用ワクチン

Also Published As

Publication number Publication date
AU2007276219B2 (en) 2013-10-03
ES2525732T3 (es) 2014-12-29
BRPI0714326A2 (pt) 2013-05-07
SG173377A1 (en) 2011-08-29
IL196471A0 (en) 2011-08-01
ES2437082T3 (es) 2014-01-08
BRPI0715581A2 (pt) 2013-04-24
EP2040742A2 (en) 2009-04-01
ZA200900386B (en) 2014-03-26
NO20090178L (no) 2009-02-09
MX2009000650A (es) 2009-07-02
SG173363A1 (en) 2011-08-29
US9364525B2 (en) 2016-06-14
AU2007276217A1 (en) 2008-01-24
MA30670B1 (fr) 2009-08-03
CA2657353A1 (en) 2008-01-24
US20100150998A1 (en) 2010-06-17
CR10561A (es) 2009-04-29
EP2040743B1 (en) 2013-10-02
JP2009543846A (ja) 2009-12-10
AU2007276217A8 (en) 2009-02-26
MX2009000655A (es) 2009-07-02
AU2007276219A1 (en) 2008-01-24
EA200900032A1 (ru) 2011-02-28
CA2657279A1 (en) 2008-01-24
AU2007276217B2 (en) 2013-08-29
NO20090177L (no) 2009-02-16
WO2008009652A2 (en) 2008-01-24
CO6150187A2 (es) 2010-04-20
US9592282B2 (en) 2017-03-14
JP5222289B2 (ja) 2013-06-26
TW200819462A (en) 2008-05-01
JP5592110B2 (ja) 2014-09-17
EP2040742B1 (en) 2014-10-29
MA30671B1 (fr) 2009-08-03
WO2008009650A2 (en) 2008-01-24
JP2009543569A (ja) 2009-12-10
IL196410A0 (en) 2011-08-01
NZ574239A (en) 2011-12-22
CO6150189A2 (es) 2010-04-20
AR061894A1 (es) 2008-10-01
NZ574238A (en) 2012-02-24
KR20090094213A (ko) 2009-09-04
US20100062028A1 (en) 2010-03-11
PE20080428A1 (es) 2008-05-15
WO2008009652A3 (en) 2008-05-08
KR20090092752A (ko) 2009-09-01
EA200900033A1 (ru) 2009-12-30
WO2008009650A3 (en) 2008-04-10
EP2040743A2 (en) 2009-04-01

Similar Documents

Publication Publication Date Title
CR10555A (es) Vacunas para malaria
MX353706B (es) Anticuerpos contra csf-1r humano y usos de los mismos.
CR20150625A (es) Composición que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
CL2016002816A1 (es) Anticuerpos anti-cd 134 (ox40) y usos de los mismos (divisional de sol. n° 631-14).
MX2009005414A (es) Formulaciones liquidas de anticuerpo antirrabico.
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
JOP20200039A1 (ar) مُستحضر صيدلي يشتمل على hcg مأشوب
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
CO6491045A2 (es) Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas
EA200970247A1 (ru) Способ получения оптического активного n-защищенного 3-аминопирролидина или оптически активного n-защищенного 3-аминопиперидина и соответствующих кетонов путем оптического разделения рацемических смесей аминов с использованием бактериальной омега-трансаминазы
GT201400049A (es) "anticuerpos a pcsk9 y usos de los mismo"
ECSP088778A (es) Formulacion de un anticuerpo monoclonal humano anti-igf-1r
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
BR112014012275A2 (pt) purificação de proteína com a utilização de tampão bis-tris
EA201170396A1 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
SG178886A1 (en) Humanized anti-cdcp1 antibodies
AR088920A1 (es) Purificacion de anticuerpos anti-c-met
EA201391515A1 (ru) Инактивированная вакцина вируса денге
DK1694706T3 (da) Modificeret anti-CD52-antistof
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
EA201390467A1 (ru) Композиции антител и способы применения
WO2012047267A3 (en) Polyvalent immunogen
EA200800601A1 (ru) Связывающие fas антитела
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)